Detail
| LncRNA Name | MAPT-AS1 |
| Synonyms | NA |
| Region | GRCh38_17:45799390-45895630 Sequence |
| Ensembl | ENSG00000264589 |
| RefSeq | NR_024559 |
| Circulating | ✘ |
| Drug-resisitant | ✘ |
| Prognostic | ✘ |
| MiRNA | ✘ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, Western blot, in vitro knockdown |
| Sample | breast cancer tumor tissues, breast cell lines (MDA-MB-231, BT-549 and SK-BR-3, MDA-MB-468 and MDA-MB-436, MCF-10A) |
| Expression Pattern | up-regulated |
| Function Description | ER-negative patients with younger age (<60), larger tumors (â?¥2cm), metastatic lymph nodes and stages (III-IV) had higher expression of MAPT-AS1. MAPT-AS1 is correlated with the cell growth, invasiveness and paclitaxel resistance by regulating its natural comparable sense transcripts MAPT in ER-negative breast cancer cells. The result revealed that MAPT-AS1 overexpression could partially protect the MAPT mRNA from degradation, while MAPT-AS1 knockdown decreased the stability of MAPT mRNA. Meanwhile, MAPT knockdown decreased the expression of MAPT-AS1 mRNA. MAPT-AS1 expressed coordinately with MAPT in breast tumor tissues. |
| Pubmed ID | 29441192 |
| Year | 2018 |
| Title | Knockdown of LncRNA MAPT-AS1 inhibites proliferation and migration and sensitizes cancer cells to paclitaxel by regulating MAPT expression in ER-negative breast cancers. |
| External Links |
| Links for MAPT-AS1 | GenBank HGNC lncrnadb Noncode |
| Links for breast cancer | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.